About Neurogeneration
Neurogeneration is a Healthcare company based in Beverly Hills (United States) founded in 1996. It operates as an early stage biotherapeutics company using autologous stem cells for Parkinsons and other diseases. The company was acqui-hired. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells. Similar companies include Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma and 5 more; 10 of its 10 listed similar companies have raised funding.
Company details
Neurogeneration is an early stage Biotech using autologous stem cells for Parkinsons treatment and other indications like Alzheimers Disease, Epilepsy, Spinal Cord injury, Stroke and MSALS. It pioneered in 1998, cell therapies via human transplantation using autologous neural stem cells-derived neurons for advanced Parkinsons disease. Neurogeneration was acquired in 2001 by Theratechnologies, a Canadian life science company, its subsidiary Celmed Biosciences furthered its development along with other cell therapy programs. Neurogeneration was reacquired in June of 2005 and the Parkinsons treatment started Phase II trials. The company Siragen was spun off from Neurogeneration.
- Headquarters Beverly Hills, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website neurogeneration.com
- Social LinkedIn
Similar companies to Neurogeneration
Neurogeneration has 10 listed similar companies in our database, 10 of them funded. They include Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| entradatx.com | 2016 | Boston, United States | $175.25M | 122 | Biologics platform developed for intracellular delivery in rare diseases. | |
| adamaspharma.com | 2002 | Emeryville, United States | $68.03M | 142 | Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics. | |
| sonomabio.com | 2012 | San Francisco, United States | $335M | 74 | T-cell-based therapies for autoimmune and degenerative diseases are developed. | |
| intracellulartherapies.com | 2002 | New York, United States | $80.87M | 600 | Developer of therapeutics for psychiatric and neurologic diseases | |
| juvlabs.com | 2017 | Dublin, Ireland | $289.89M | – | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| bluerocktx.com | 2016 | Boston, United States | $225M | 138 | Stem cell therapies are developed for cardiovascular and neurological diseases. |
Detailed similar companies of Neurogeneration
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neurogeneration
Websites that share an audience with Neurogeneration (neurogeneration.com).
Websites whose visitors overlap most with Neurogeneration. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| intercytex.com | 100% | – | – | View details | |
| stemedica.com | 81% | – | – | View details | |
| pluristem.com | 78% | – | – | View details |
Top companies in Cell Therapy
10 companies that operate in the same segment as Neurogeneration (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neurogeneration
Neurogeneration was founded in 1996.
Neurogeneration is headquartered in Beverly Hills, United States. It is registered at Beverly Hills, California, United States.
Neurogeneration is an early stage Biotech using autologous stem cells for Parkinsons treatment and other indications like Alzheimers Disease, Epilepsy, Spinal Cord injury, Stroke and MSALS. It pioneered in 1998, cell therapies via human transplantation using autologous neural stem cells-derived neurons for advanced Parkinsons disease. Neurogeneration was acquired in 2001 by Theratechnologies, a Canadian life science company, its subsidiary Celmed Biosciences furthered its development along with other cell therapy programs. Neurogeneration was reacquired in June of 2005 and the Parkinsons treatment started Phase II trials. The company Siragen was spun off from Neurogeneration.
Neurogeneration's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.